SQI Diagnostics completes acquisition of Precision Biomonitoring's human diagnostic testing business

1 minute read
14 February 2022

On February 14, 2022, SQI Diagnostics Inc. ("SQI") (TSXV: SQD) (OTCQB: SQIDF) announced that it had completed its previously announced asset acquisition of Precision Biomonitoring Inc.'s ("PBI") human diagnostic COVID-19 PCR testing business and its TripleLock™ molecular diagnostic testing technology.

Pursuant to the terms of the definitive agreement, SQI acquired the assets through its wholly owned subsidiary, SQI Diagnostic Systems Inc., for aggregate consideration of $6,825,000 consisting of cash and common shares in the capital of SQI.

Gowling WLG advised PBI with respect to this transaction with a team led by Thomas Hunter and that included Irena Kramer and Michelle Kumar.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.